Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity

The objective of this study is to further analyze recombinant rabies virus-vectored SARS-CoV-2 vaccine, CORAVAX, as an effective COVID-19 vaccine strategy. CORAVAX has proven immunogenic and protective against SARS-CoV-2 in animal models. Here, we have screened adjuvants for the highest quality anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yankowski, Catherine, Wirblich, Christoph, Kurup, Drishya, Schnell, Matthias J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508099/
https://www.ncbi.nlm.nih.gov/pubmed/36151100
http://dx.doi.org/10.1038/s41541-022-00532-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508099/
https://www.ncbi.nlm.nih.gov/pubmed/36151100
http://dx.doi.org/10.1038/s41541-022-00532-7

Ejemplares similares